|
🐬
|
Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects
R. García-mayor,
Angel J. Perez,
A. Gándara,
A. Andrade,
F. Mallo,
F. Casanueva
|
4 |
1993 |
4
🐬
|
|
🐢
|
Long-term remission following antithyroid drug withdrawal in patients with Graves’ hyperthyroidism: parameters with prognostic value
R. García-mayor,
P. Álvarez-Vázquez,
E. Fluiters,
D. Valverde,
A. Andrade
|
4 |
2018 |
4
🐢
|
|
🐬
|
Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination.
C. Paramo,
E. Fluiters,
J. de la Fuente,
A. Andrade,
R. García-mayor
|
3 |
2001 |
3
🐬
|
|
🐬
|
Altered growth hormone response after growth hormone releasing hormone administration in chronic renal failure
R. V. G. Garcia,
A. Andrade,
J. Pérez,
M. Courel,
F. Casanueva
|
2 |
1991 |
2
🐬
|
|
🐬
|
The relationship between disturbed metabolism of vitamin D and bone disease in chronic renal failure.
J. Kanis,
R. Russell,
C. Taylor,
T. Cundy,
A. Andrade,
G. Heynen
|
2 |
1979 |
2
🐬
|
